Dr. Raje discusses results from a large phase III trial comparing denosumab with zoledronic acid for delaying the time to a skeletal-related complication in patients with myeloma.
Noopur Raje, MD: Denosumab Versus ZA for Myeloma-Related Bone Disease
Recent Articles
Ibrutinib Versus FCR: A “Paradigm Shift” for Younger Patients With Treatment-Naïve CLL
In patients with previously untreated chronic lymphocytic leukemia (CLL), treatment with an ibrutinib-based therapy improved progression-free survival (PFS) and overall survival (OS), compared with...
Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism
Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...
Ravulizumab: A New Treatment Option for PNH?
Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
A Rapid, Inexpensive Screening Test for Sickle Cell Disease in Uganda
Erik Serrao, PhD, discusses the HemoTypeSC test, which provides a rapid, cost-effective screening method for sickle cell disease in newborns living in limited-resource settings.
Elotuzumab Combination Prevents Progression from Smoldering to Symptomatic Myeloma
Irene Ghobrial, MD, shares results from a phase II trial, in which 84 percent of patients with high-risk smoldering multiple myeloma responded to treatment...
Current Issue
December 2018, Volume 4, Issue 14
This issue features a look at the consequences of medical errors, an update on the Cancer Moonshot Initiative, a preview of 2018 ASH Annual Meeting, and more.
